Trials / Withdrawn
WithdrawnNCT05053321
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 26 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with Valbenazine for a total of 6 weeks. Improvement in TD will be assessed as well and correlated with reduction in demoralization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valbenazine | All participants will be treated with Valbenazine for 6 weeks. |
Timeline
- Start date
- 2024-10-18
- Primary completion
- 2025-10-18
- Completion
- 2025-10-18
- First posted
- 2021-09-22
- Last updated
- 2025-07-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05053321. Inclusion in this directory is not an endorsement.